Bli medlem
Bli medlem

Du är här


Biofrontera AG: Biofrontera starts Sales and Marketing of Ameluz® in Spain

Biofrontera AG / Biofrontera starts Sales and Marketing of Ameluz® in Spain.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
* Key Account Manager transfers from Allergan to Biofrontera
* Biofrontera will capture full margin of Ameluz®sales with immediate effect
* International launch event with leading dermatologists in Valencia - 27/28

Leverkusen, Germany, 25 March 2015 - Biofrontera AG (FSE: B8F), the
biopharmaceutical company focusing on skin cancer, has now taken over
marketing and sales activities for Ameluz®and BF-RhodoLED®in Spain as planned
in line with its announcement made on 7 November 2014. Previously, these
functions were performed by distribution partner Allergan Pharmaceuticals.

The successful transition has been prepared over several months in cooperation
with Allergan. In addition, Biofrontera is pleased to announce that Antonio
Lopez Belda, former Key Account Manager for dermatology at Allergan, has
transferred to Biofrontera, with immediate effect. Mr. Lopez led the launch
of Ameluz in Spain and has successfully developed the market since. This will
allow for continuity with all established contacts within hospitals and

"Spain is one of the most important European markets for photodynamic
therapy," said Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "In the new
structure, we can now collect the entire margin of the Ameluz®sales for
Biofrontera. Thus, our profitability in Spain will increase significantly. It
is anticipated that the additional investment in sales and marketing should
pay off within one year."

The new Biofrontera subsidiary will be named 'Biofrontera Pharma GmbH,
sucursal en España' and is based in Cornellá de Llobregat near Barcelona. In
the current year Biofrontera expects sales in the mid six-digit Euro range in

On the occasion of the launch, Biofrontera will hold an international
symposium in Valencia from March 27 to 28, and expects some 50 dermatologists
from all over Spain to attend the event.


Enquiries, please contact:

| Biofrontera AG +49 (0) 214 87 63 2 0 |
| |
|Prof. Hermann Lübbert, Chief Executive Officer |
|Thomas Schaffer, Chief Financial Officer |
| |
| IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514 |
| |
|Jürgen Benker |
| Nomad and Broker: Shore Capital +44(0) 20 7408 4090 |
| |
|Bidhi Bhoma / Toby Gibbs |
| IR UK: Seton Services +44(0) 20 7603 6797 |
| |
|Toni Vallen |
| Financial PR: Gable Communications +44(0) 20 7193 7463 |
| |
|John Bick +44 (0)7872 061007 |

TheBiofrontera Group
(FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product
, a prescription drug which is approved in Europe for the treatment of mild
and moderate actinic keratosis (superficial skin cancer) with photodynamic
therapy (light therapy). Biofrontera is the first German pharmaceutical
start-up company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz®to be approved for basal cell
carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United

The company also markets the Belixos®dermatological range of cosmetics.
Belixos®products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the
moment, Belixos®cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.

This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These
forward-looking statements reflect the opinion of Biofrontera at the time of
this communication and involve certain known and unknown risks. The actual
results achieved by Biofrontera may differ significantly from future results
or performances which are published in its forward-looking statements.
Biofrontera assumes no responsibility to update its forward-looking


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.